Mylan’s salmeterol/fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling therapies for asthma and COPD. Although other nonsubstitutable salmeterol/fluticasone propionate inhalers were recently introduced to the market (e.g., Teva’s AirDuo and its generic), their uptake has not been very robust. This Asthma and COPD Emerging Therapies series tracks the awareness, trial, and use of Wixela Inhub by U.S. physicians at one, six, and twelve months after its launch—data that should give Mylan and its competitors insight into the product’s market uptake. The series also examines physician-anticipated trends in asthma and COPD treatment, particularly with respect to the uptake of Wixela Inhub, and assesses Mylan’s promotional efforts.
What are U.S. physicians’ awareness of, familiarity with, and perceptions related to Wixela Inhub? Among prescribers of Wixela Inhub, to which patients are they prescribing it, what are the reasons for prescribing it, and how satisfied are they with Wixela Inhub? How do prescribers and nonprescribers compare across key metrics? How are the trial and adoption of Wixela Inhub tracking compared with other recent products for asthma and COPD?
Geography : United States
Primary Research : Survey of approximately 75 U.S. physicians for each wave
Key metrics included :
Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.